CSIMarket
 
Chimerix inc   (NASDAQ: CMRX)
Other Ticker:  
 
 
Price: $3.9600 $0.13 3.394%
Day's High: $3.99 Week Perf: 11.55 %
Day's Low: $ 3.81 30 Day Perf: 32.44 %
Volume (M): 757 52 Wk High: $ 4.07
Volume (M$): $ 2,999 52 Wk Avg: $1.24
Open: $3.83 52 Wk Low: $0.10



 Market Capitalization (Millions $) 355
 Shares Outstanding (Millions) 90
 Employees 201
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -84
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

Chimerix Inc
Chimerix Inc is an American biopharmaceutical company that focuses on developing medicines for various viral infections and cancer treatment. The company has been operational since 2002 and is headquartered in Durham, North Carolina.

Chimerix's primary focus is on the development of antiviral therapies for life-threatening viral infections. One of its most notable products is brincidofovir, an antiviral drug that is used to treat cytomegalovirus (CMV). CMV is a viral infection that is prevalent in people with weakened immune systems, such as organ transplant recipients and HIV/AIDS patients.

In addition to CMV, Chimerix is also working on developing therapies for other viral infections such as adenovirus, BK virus, and human papillomavirus (HPV). The company's research in this area involves the use of small molecules to target viral proteins.

Apart from antiviral therapies, Chimerix is also involved in the development of oncology drugs. The company's lead oncology candidate is dociparstat sodium, a drug that targets the heparanase enzyme, which plays a critical role in the development and spread of cancer cells. Dociparstat sodium is being investigated for its potential use in the treatment of acute myeloid leukemia (AML) and multiple myeloma.

The company has also developed a proprietary lipid nanoparticle delivery technology platform, which is being used to enhance the delivery of RNA-based drugs, including gene therapy and gene editing.

As of 2021, Chimerix has a research and development team of over 60 scientists and researchers working in their state-of-the-art facility in Durham. The company's innovative approach to drug development has earned it numerous accolades, including the Frost & Sullivan 2018 Best Practices Award for New Product Innovation.


   Company Address: 2505 Meridian Parkway Durham 27713 NC
   Company Phone Number: 806-1074   Stock Exchange / Ticker: NASDAQ CMRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY     
JNJ     
LLY     
MRK     
TEVA     
VTRS     
• View Complete Report
   



Stock Market Announcement

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Published Fri, Oct 18 2024 8:31 PM UTC

Chimerix Grants Inducement Award to New Employee Under Nasdaq Rule 5635(c)(4)In the realm of biotech investments and corporate development, Chimerix, Inc. (NASDAQ: CMRX) has demonstrated a strategic approach to attracting and retaining top talent within its ranks. Building on a continuing strategy to expand and enhance its operational capabilities, the company announced on ...

Stock Market Announcement

Chimerix Grants Inducement Award to New Employee, Impact on Company Shares Assessed

Published Fri, Aug 30 2024 8:05 PM UTC



Chimerix, a leading biopharmaceutical company based in Durham, North Carolina, recently announced the granting of an inducement award to a new employee under the Nasdaq Listing Rule 5635(c)(4). This article will outline the facts surrounding the award and assess its potential impact on Chimerix s stock prices. It is important to note that at the time of writing, Ch...

Stock Market Announcement

Paving the Way for Growth: Chimerix Continues Inducement Grants Amidst Share Price Volatility

Published Fri, Jul 5 2024 8:05 PM UTC


In a recent press release, Chimerix (NASDAQ:CMRX) announced the granting of inducement awards to two new employees in the form of non-statutory stock options. This move, approved by the Compensation Committee of Chimerix s Board of Directors, is seen as a strategic decision to attract top talent and align the interests of new employees with those of the company. This an...

Chimerix Inc

Chimerix Inc Faces Challenges Amidst Share Price Decline

Chimerix Inc, a biopharmaceutical company based in Durham, N.C., recently experienced a drop in its shares by -10.99% during the month of April. This decline brings the share price to 0.49% in the past 90 days. Additionally, Chimerix Inc shares are currently trading only 6.2% above its 52-week low. These numbers indicate some challenges faced by the company in recent times.
Looking at the financial performance of Chimerix Inc from January to March 31, 2024, it reported a shortfall per share of $-0.25 compared to $-0.24 a year ago. This signifies a slight increase in the shortfall. Additionally, the revenue remained unchanged at $0.00 million from $0.28 million in the corresponding reporting period a year ago, and sequentially from $0.00 million. The company experienced a net shortfall of $-21.869 million, which is higher than the $-21.372 million reported a year ago. Moreover, the level of accounts receivable has declined to $0.0 million, leading some analysts to suspect slowing demand.

Shares

Chimerix Grants Inducement Awards - A Positive Move for Employee Retention and Company Growth

Published Tue, Apr 16 2024 8:05 PM UTC



In a recent press release, Chimerix (NASDAQ: CMRX), a leading biopharmaceutical firm based in Durham, N.C., announced the granting of inducement awards to four new employees. The Compensation Committee of Chimerix s Board of Directors authorized the awards as part of a strategic move to attract and retain top talent. These awards come in the form of non-statutory s...







Chimerix Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com